LexaGene Holdings Inc. Quarterly Research and Development Expense in USD from Q3 2021 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
LexaGene Holdings Inc. quarterly Research and Development Expense history and growth rate from Q3 2021 to Q4 2022.
  • LexaGene Holdings Inc. Research and Development Expense for the quarter ending November 30, 2022 was $887K, a 41.1% decline year-over-year.
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2022 $887K -$619K -41.1% Sep 1, 2022 Nov 30, 2022 10-Q 2023-01-17
Q3 2022 $1.12M -$485K -30.2% Jun 1, 2022 Aug 31, 2022 10-Q 2022-10-18
Q4 2021 $1.51M Sep 1, 2021 Nov 30, 2021 10-Q 2023-01-17
Q3 2021 $1.6M Jun 1, 2021 Aug 31, 2021 10-Q 2022-10-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.